Navigation Links
Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Date:6/23/2009

Completed NDA submission could lead to marketing approval in Q4-2009

SEATTLE, June 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.

"This is a major milestone for CTI and is the cornerstone of a turnaround strategy for us in meeting our goals of becoming a profitable operating business," said James A. Bianco, M.D., Chief Executive Officer of CTI. "With more than 76,000 pages and 500,000 hyperlinks this submission represents the hard work of many CTI employees dedicated to making a difference in the lives of patients with cancer. This also represents a significant advance in the treatment of patients with relapsed/refractory aggressive NHL, a patient population which the FDA has acknowledged represents an unmet medical need."

About the PIX 301 EXTEND Trial

CTI's EXTEND (PIX 301) clinical trial (the "PIX 301 EXTEND trial") was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population as selected by the physician.

CTI previously announced that its pivotal PIX 301 EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... shows that incisionless transcatheter aortic valve replacement (TAVR) ... percent and has no impact on post-operative vascular ... which requires an incision in the groin. The ... of Circulation: Cardiovascular Interventions . , TAVR ... a traditional open-heart surgical approach. It is a ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
(Date:7/24/2014)... Angeles, CA (PRWEB) July 24, 2014 On ... loved ones will descend upon the Embassy Suites LAX North ... Conference hosted by DiabetesSisters and the first time it has ... first time for the organization to open the entire event ... As the only conference of its kind worldwide for women ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Human semen is ... microbes might have a role to play in both HIV ... that bacteria in semen -- the "microbiome" -- play a ... by infected men. They say the findings point to possible ... study couldn,t prove that the bacteria was causing changes in ...
Breaking Medicine News(10 mins):Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Bacteria in Semen May Affect HIV Transmission, Levels: Study 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: